CLNN
Clene Inc. NASDAQ Listed Oct 18, 2018$5.77
After hrs
$5.69
-1.42%
Mkt Cap $56.9M
52w Low $3.36
26.4% of range
52w High $12.50
50d MA $6.31
200d MA $6.56
P/E (TTM)
-1.8x
EV/EBITDA
—
P/B
—
Debt/Equity
-1.2x
ROE
148.8%
P/FCF
-3.1x
RSI (14)
47.30
ATR (14)
$0.40
Beta
0.62
50d MA
$6.31
200d MA
$6.56
Avg Volume
140.1K
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
6550 South Millrock Drive · Salt Lake City, UT 84121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.74 | -0.88 | -18.9% | 5.92 | +1.4% | -3.4% | +4.2% | +2.9% | +7.2% | -10.7% | — |
| Nov 13, 2025 | AMC | -0.60 | -0.85 | -41.7% | 7.30 | -4.0% | +16.7% | +1.1% | -0.6% | +1.1% | +1.3% | — |
| Aug 14, 2025 | AMC | -0.49 | -0.78 | -59.2% | 3.60 | -1.9% | +0.6% | +17.1% | +5.7% | +25.4% | -5.0% | — |
| May 7, 2025 | AMC | -1.10 | -0.50 | +54.5% | 2.55 | +7.5% | +1.2% | +1.9% | +3.4% | -2.9% | +0.8% | — |
| Mar 24, 2025 | AMC | -1.21 | -1.67 | -38.0% | 3.92 | -2.3% | -11.7% | +2.3% | -10.2% | +1.3% | -4.3% | — |
| Nov 13, 2024 | AMC | -1.34 | -1.22 | +9.0% | 4.82 | +1.9% | -2.7% | -3.4% | -2.9% | +5.9% | -12.2% | — |
| Aug 7, 2024 | AMC | -1.60 | -1.06 | +33.8% | 4.50 | -3.1% | -2.0% | +14.7% | +1.0% | -0.8% | -2.2% | — |
| May 8, 2024 | AMC | -1.80 | -1.80 | +0.0% | 7.80 | +1.3% | -0.8% | -0.1% | +1.2% | -1.8% | -0.4% | — |
| Mar 13, 2024 | AMC | -1.40 | -1.20 | +14.3% | 8.79 | +0.1% | -4.4% | -4.8% | +1.8% | -1.5% | -0.2% | — |
| Nov 7, 2023 | AMC | -2.00 | -0.40 | +80.0% | 8.40 | +7.1% | -1.0% | -3.6% | +12.2% | +4.3% | -6.8% | — |
| Aug 14, 2023 | AMC | -2.60 | -2.40 | +7.7% | 14.50 | +1.7% | +2.8% | -2.1% | -2.6% | +0.0% | -2.8% | — |
| May 12, 2023 | AMC | -3.20 | -3.00 | +6.2% | 17.60 | +0.0% | +1.7% | +0.6% | +2.2% | +0.0% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.92 | $6.00 | +1.4% | -3.4% | +4.2% | +2.9% | +7.2% | -10.7% |
| Mar 12 | D. Boral Capital | Maintains | Buy → Buy | — | $5.58 | $5.58 | +0.0% | +6.1% | -3.4% | +4.2% | +2.9% | +7.2% |
| Jan 9 | D. Boral Capital | Maintains | Buy → Buy | — | $5.97 | $5.97 | +0.0% | +7.2% | -19.1% | -1.5% | +0.4% | -0.2% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $6.23 | $6.14 | -1.4% | +7.2% | +3.0% | -1.6% | -7.8% | +3.0% |
| Dec 3 | D. Boral Capital | Maintains | Buy → Buy | — | $9.26 | $9.30 | +0.4% | -22.0% | -12.9% | -8.3% | +1.6% | +6.3% |
| Nov 17 | D. Boral Capital | Maintains | Buy → Buy | — | $8.52 | $8.38 | -1.6% | +1.1% | -0.6% | +1.1% | +1.3% | +5.8% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $6.05 | $6.14 | +1.5% | -2.8% | +0.0% | +1.9% | +0.7% | +15.6% |
| Sep 10 | Benchmark | Maintains | Buy → Buy | — | $6.60 | $6.60 | +0.0% | -2.0% | -4.5% | -6.1% | +7.8% | +1.3% |
| Aug 21 | D. Boral Capital | Maintains | Buy → Buy | — | $5.62 | $5.50 | -2.1% | -5.0% | +6.0% | -5.8% | +0.9% | +0.0% |
| Aug 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.62 | $3.66 | +1.1% | +17.1% | +5.7% | +25.4% | -5.0% | +6.0% |
| Aug 14 | D. Boral Capital | Maintains | Buy → Buy | — | $3.65 | $3.52 | -3.6% | -1.4% | +0.6% | +17.1% | +5.7% | +25.4% |
| Jul 18 | D. Boral Capital | Maintains | Buy → Buy | — | $3.90 | $3.95 | +1.3% | -2.1% | +1.3% | -1.6% | -1.8% | -2.1% |
| Jun 30 | D. Boral Capital | Maintains | Buy → Buy | — | $3.76 | $3.70 | -1.6% | +4.0% | -0.3% | +1.3% | -1.3% | -0.8% |
| May 8 | Benchmark | Maintains | Buy → Buy | — | $2.55 | $2.74 | +7.5% | +1.2% | +1.9% | +3.4% | -2.9% | +0.8% |
| May 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.55 | $2.74 | +7.5% | +1.2% | +1.9% | +3.4% | -2.9% | +0.8% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $2.75 | +3.4% | +7.5% | +4.9% | +1.3% | -0.3% | +1.7% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.66 | $2.75 | +3.4% | +7.5% | +4.9% | +1.3% | -0.3% | +1.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $3.83 | -2.3% | -11.7% | +2.3% | -10.2% | +1.3% | -4.3% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $4.14 | $4.20 | +1.4% | -5.3% | -11.7% | +2.3% | -10.2% | +1.3% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.14 | $4.20 | +1.4% | -5.3% | -11.7% | +2.3% | -10.2% | +1.3% |
| Mar 12 | D. Boral Capital | Maintains | Buy → Buy | — | $4.54 | $4.40 | -3.1% | -3.1% | -0.7% | +1.4% | +2.9% | -2.2% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.40 | -3.1% | -3.1% | -0.7% | +1.4% | +2.9% | -2.2% |
| Feb 25 | D. Boral Capital | Maintains | Buy → Buy | — | $4.23 | $4.47 | +5.7% | +0.9% | +0.0% | +3.5% | +1.8% | -3.8% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.23 | $4.47 | +5.7% | +0.9% | +0.0% | +3.5% | +1.8% | -3.8% |
| Feb 6 | D. Boral Capital | Maintains | Buy → Buy | — | $4.63 | $4.61 | -0.4% | -4.5% | -1.1% | +4.1% | +0.7% | +0.4% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $4.12 | $4.32 | +4.9% | +4.4% | +2.3% | +7.3% | +5.9% | +1.6% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $4.75 | $4.77 | +0.4% | +3.8% | +0.8% | -0.2% | -0.2% | -5.1% |
| Nov 22 | Benchmark | Maintains | Buy → Buy | — | $4.01 | $4.02 | +0.2% | +4.0% | -2.2% | -4.9% | +7.0% | +0.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.91 | +1.9% | -2.7% | -3.4% | -2.9% | +5.9% | -12.2% |
| Nov 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.82 | $4.91 | +1.9% | -2.7% | -3.4% | -2.9% | +5.9% | -12.2% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $5.30 | $5.11 | -3.6% | -9.1% | -2.7% | -3.4% | -2.9% | +5.9% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.40 | $5.40 | +0.0% | -2.4% | +1.5% | +9.7% | +8.7% | -2.2% |
| Oct 24 | EF Hutton | Maintains | Buy → Buy | — | $5.40 | $5.40 | +0.0% | -2.4% | +1.5% | +9.7% | +8.7% | -2.2% |
| Oct 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.95 | $5.00 | +1.0% | +7.1% | +0.4% | -3.6% | +14.0% | -5.8% |
| Oct 2 | EF Hutton | Maintains | Buy → Buy | — | $4.60 | $4.60 | +0.0% | +6.3% | +1.2% | +7.1% | +0.4% | -3.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.74 | $6.70 | -0.6% | -17.1% | -5.4% | -5.1% | +3.4% | -3.7% |
| Sep 16 | EF Hutton | Maintains | Buy → Buy | — | $6.74 | $6.70 | -0.6% | -17.1% | -5.4% | -5.1% | +3.4% | -3.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.41 | $4.42 | +0.2% | +14.7% | +1.0% | -0.8% | -2.2% | -1.6% |
| Aug 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.00 | $4.12 | +3.0% | +47.0% | -23.5% | -2.0% | +14.7% | +1.0% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.82 | $7.78 | -0.5% | +1.4% | -3.5% | -5.9% | -2.5% | +5.1% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $8.28 | +10.8% | +1.7% | +2.9% | +1.4% | -3.5% | -5.9% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.02 | $7.25 | +3.3% | -3.1% | +8.5% | -7.6% | -3.5% | -4.0% |
| May 23 | Benchmark | Maintains | Buy → Buy | — | $7.28 | $7.52 | +3.3% | -4.3% | +0.7% | -3.1% | +8.5% | -7.6% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.83 | $7.78 | -0.6% | -0.4% | -0.8% | -0.1% | +1.2% | -1.8% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.20 | $7.20 | +16.1% | +9.5% | -2.8% | +5.8% | -4.6% | +0.6% |
| Mar 20 | Benchmark | Maintains | Buy → Buy | — | $8.02 | $8.02 | +0.0% | -0.2% | +6.2% | +4.5% | -3.2% | -1.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.88 | $9.76 | +9.9% | -1.0% | -4.4% | -4.8% | +1.8% | -1.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.00 | $10.00 | +0.0% | -11.0% | -0.2% | -1.0% | -4.4% | -4.8% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.99 | $9.20 | +2.3% | -4.3% | +0.0% | -0.8% | -0.4% | +2.1% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.30 | $6.76 | -34.4% | -38.8% | -7.9% | -5.0% | -5.6% | +7.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | Ugwumba Chidozie10% | — | Sell | 73,296 | $6.20 | $454K | 103,417 | +8.46% | +8.15% |
| May 11, 2026 | Ugwumba Chidozie10% | — | Sell | 22,177 | $6.75 | $150K | 176,713 | +8.46% | +8.15% |
| May 4, 2026 | Ugwumba Chidozie10% | — | Sell | 72,884 | $6.80 | $496K | 198,890 | +8.81% | +0.00% |
| May 1, 2026 | Ugwumba Chidozie10% | — | Sell | 5,795 | $6.01 | $35K | 271,774 | +8.81% | +0.00% |
| Apr 30, 2026 | Ugwumba Chidozie10% | — | Sell | 5,736 | $6.08 | $35K | 277,569 | -0.32% | +3.21% |
| Apr 29, 2026 | Ugwumba Chidozie10% | — | Sell | 12,170 | $5.63 | $69K | 283,305 | -0.32% | +3.21% |
| Apr 28, 2026 | Ugwumba Chidozie10% | — | Sell | 1,591 | $5.90 | $9K | 295,475 | -0.32% | +3.21% |
8-K · 5.02
!!! Very High
Clene Inc. -- 8-K 5.02: Executive Change
May 22
8-K · 2.02
!! High
Clene Inc. -- 8-K 2.02: Earnings Results
Clene Inc. disclosed quarterly earnings results via press release, providing investors with updated financial performance and operational metrics for the period.
May 14
8-K · 8.01
!! High
Clene Inc. -- 8-K 8.01: Material Event / Announcement
Clene Inc. announced a securities offering on May 5, 2026, though specific terms require reviewing the attached press release for investor impact details.
May 5
8-K · 8.01
!! High
Clene Inc. -- 8-K 8.01: Material Event / Announcement
Clene received FDA meeting minutes confirming potential accelerated approval pathway eligibility for its ALS treatment, a positive development that could expedite NDA filing and market entry for CLNN.
May 4
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CLNN retains flexibility to exit its NYU research partnership while protecting proprietary technology, reducing downside risk if the collaboration underperforms or diverts resources from core operations.
Mar 17
8-K
Unknown — 8-K Filing
Clene reported 2025 full-year results and CNM-Au8 updates for its neurodegeneration pipeline; investors should monitor clinical trial progress and cash runway as a pre-revenue biotech.
Mar 12
8-K · 8.01
!! High
Clene Inc. -- 8-K 8.01: Material Event / Announcement
Clene Inc. announced a material event via press release filing, though specific details require reviewing the exhibit to assess impact on shareholders.
Feb 24
Valuation
Market Cap
$56.9M
Enterprise Value
$65.2M
P/E (TTM)
-1.78x
Forward P/E
—
PEG Ratio
0.04x
P/B
—
P/S
424.52x
P/FCF
-3.06x
EV/EBITDA
—
Shares Out
9.9M
Financials (TTM)
Revenue
$134K
Net Income
-$33.5M
EBITDA
-$29.2M
Free Cash Flow
-$18.6M
Op Cash Flow
-$18.5M
EPS Basic
$-2.65
EPS Diluted
$-3.25
EPS Forward
$-2.06
Gross Margin
-182.1%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$18.1M
Total Liab.
$35.7M
Total Equity
-$17.6M
Cash
$5.2M
LT Debt
$13.5M
Book Value/Sh
$-1.78
Debt/Equity
-1.23x
Current Ratio
0.83
Quick Ratio
0.83
Returns & Growth
ROE
148.8%
ROA
-144.3%
ROIC
-188.6%
Rev Growth YoY
-41.5%
EPS Growth YoY
+53.3%
Price Returns
2W
-7.0%
1M
+6.5%
3M
+25.4%
6M
-36.7%
12M
+105.6%
Technicals
52W High
$12.50
52W Low
$3.36
50d MA
$6.31
200d MA
$6.56
RSI (14)
47.30
ATR (14)
$0.40
Beta
0.62
Avg Volume
140K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$50.00
High
$50.00
Low
$50.00
Median
$50.00
Data updated apr 25, 2026 1:43am
· Source: financialmodelingprep.com